RAPT Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
RAPT Therapeutics, Inc. carries a market capitalization of 959.26M, placing it among publicly traded companies globally. Its enterprise value stands at 404.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 959.26M |
| Enterprise Value | 404.09M |
Share Statistics
RAPT Therapeutics, Inc. currently has 16.86M shares outstanding.
| Shares Outstanding | 16.86M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.84 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | -6.46 |
| P/OCF Ratio | -6.45 |
Financial Position
RAPT Therapeutics, Inc. maintains a current ratio of 12.04, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.04 |
| Quick Ratio | 11.76 |
| Debt / Equity | 1.71 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -77.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
RAPT Therapeutics, Inc.'s stock has gained approximately 590.53571% over the past 52 weeks. The 50-day moving average sits at 49.05, while the 200-day moving average is 26.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | 590.53571% |
| 50-Day Moving Average | 49.05 |
| 200-Day Moving Average | 26.91 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -111.66M, while operating income came in at -112.64M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -112.64M |
| Pretax Income | -105.64M |
| Net Income | -105.64M |
| EBITDA | -111.66M |
| EBIT | -112.64M |
| Earnings Per Share (EPS) | -4.88 |
Balance Sheet
RAPT Therapeutics, Inc. holds 157.34M in cash and equivalents against 2.60M in total debt, resulting in a net debt position of -37.93M. Total book value stands at -666.93M, with working capital of 147.67M providing operational flexibility.
| Cash & Cash Equivalents | 157.34M |
| Total Debt | 2.60M |
| Net Debt | -37.93M |
| Equity (Book Value) | -666.93M |
| Book Value Per Share | -30.78 |
| Working Capital | 147.67M |
Cash Flow
RAPT Therapeutics, Inc. produced -86.58M in operating cash flow over the past twelve months. After subtracting -84,000.00 in capital expenditures, free cash flow totaled -86.66M - equivalent to -4.00 per share.
| Operating Cash Flow | -86.58M |
| Capital Expenditures | -84,000.00 |
| Free Cash Flow | -86.66M |
| FCF Per Share | -4.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.64 |
| FCF Yield | -15.48 |
Stock Splits
RAPT Therapeutics, Inc.'s most recent stock split took place on June 17, 2025 with a 8:1 split ratio.
| Last Split Date | 6/17/2025 |
| Split Ratio | 8:1 |
Scores
RAPT Therapeutics, Inc. posts an Altman Z-Score of 17.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 17.56 |